Cord Blood Transplantation from Unrelated Donors for Children with Acute Lymphoblastic Leukemia in Japan: The Impact of Methotrexate on Clinical Outcomes

被引:16
作者
Kato, Koji [1 ]
Yoshimi, Ayami [2 ]
Ito, Etsuro [3 ]
Oki, Kentaro [4 ]
Hara, Juinichi [5 ]
Nagatoshi, Yoshihisa [6 ]
Kikuchi, Akira [7 ]
Kobayashi, Ryoji [8 ]
Nagamura-Inoue, Tokiko [9 ]
Kai, Shunro [10 ]
Azuma, Hiroshi [11 ]
Takanashi, Minoko [12 ]
Isoyama, Keiichi [13 ]
Kato, Shunichi [14 ]
机构
[1] Japanese Red Cross Nagoya First Hosp, Childrens Med Ctr, Div Hematol Oncol, Nakamura Ku, Nagoya, Aichi 4538511, Japan
[2] Nagoya Univ, Sch Med, Dept HSCT Data Management, Nagoya, Aichi 466, Japan
[3] Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 036, Japan
[4] Chiba Univ Hosp, Dept Pediat, Chiba, Japan
[5] Osaka City Gen Hosp, Dept Pediat Hematol Oncol, Osaka, Japan
[6] Kyushu Natl Canc Ctr, Paediat Sect, Fukuoka, Japan
[7] Saitama Childrens Med Ctr, Div Hematol Oncol, Iwatsuki, Saitama, Japan
[8] Hokkaido Univ, Grad Sch Med, Dept Pediat, Sapporo, Hokkaido, Japan
[9] Tokyo Cord Blood Bank, Tokyo, Japan
[10] Hyogo Cord Blood Bank, Nishinomiya, Hyogo, Japan
[11] Hokkaido Cord Blood Bank, Sapporo, Hokkaido, Japan
[12] Metro Tokyo Cord Blood Bank, Tokyo, Japan
[13] Kanagawa Cord Blood Bank, Yokohama, Kanagawa, Japan
[14] Tokai Univ, Cord Blood Bank, Isehara, Kanagawa, Japan
关键词
Cord blood transplantation; Acute lymphoblastic leukemia; HLA; Methotrexate; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; CELL TRANSPLANTATION; PLACENTAL-BLOOD; RECIPIENTS; CHEMOTHERAPY; GLOBULIN; EUROCORD;
D O I
10.1016/j.bbmt.2011.05.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cord blood transplantation (CBT) from an unrelated donor is recognized as one of the major treatment modalities in allogeneic stem cell transplantation (SCT) for children with hematologic malignancies. We analyzed the clinical outcomes of CBT for children with acute lymphoblastic leukemia (ALL) in Japan and identified the risk factors for the transplant outcomes. From 1997 to 2006, 332 children with ALL underwent CBT from unrelated donors, 270 of which had no prior transplant. Their disease statuses at transplant were first complete remission (CR) (n = 120), second CR (n = 71), and more advanced stages (n = 75). As preconditioning for SCT, total body irradiation (TBI) was given to 194 patients and, for the prophylaxis of graft-versus-host disease (GVHD), methotrexate (MTX) was given to 159 patients. The cumulative incidents of neutrophil and platelet recovery (>20 K) were 88.5% and 78.4%, respectively. The incidents of gradell-IV,III-IV acute GVHD (aGVHD), and chronic GVHD (cGVHD) were 45.6%, 20.4%, and 19.2%, respectively, and treatment-related mortality was 22.6%. The 5-year event-free survival (EFS) and overall survival (OS) at CR I, CR2, and advanced status were 47.4%, 45.5%, 15.0%, and 63.7%, 59.7%, and 20.7%, respectively. Multivariate analysis revealed that MTX with calcineurin inhibitor (CNI) was associated with decreased incidence of grade II-IV GVHD (CNI alone: hazard ratio [HR] = 1.74, 95% confidence interval [Cl] = 1.06-2.83, P =.027; CNI + prednisolone (PSL), HR = 1.61,95% CI = 1.03-2.50, P =.036), III-IV aGVHD (CNI alone: HR = 3.02,95% Cl = 1.55-5.91, P = 0.001; CNI + PSL, HR = 1.89,95% Cl = 0.93-3.83, P =.078), or cGVHD (CNI alone: HR = 1.78,95% Cl = 0.83-3.82, P =.143; CNI + PSL, HR = 2.44, 95% Cl = 1.24-4.82, P =.01), compared with CNI alone or CNI + PSL. At an advanced stage of disease, GVHD prophylaxis with MTX + CNI is associated with improved OS compared with CNI alone (CNI alone: HR = 3.20, 95% Cl = 1.43-7.15, P =.005; CNI + PSL, HR = 1.47, Cl = 0.67-3.20, P =.332). Our retrospective study showed that CBT for children with ALL is feasible and GVHD prophylaxis with MTX + CNI is associated with significant favorable outcomes in prevention of aGVHD and cGVHD as well as survival advantage in advanced cases. Biol Blood Marrow Transplant 17: 1814-1821 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
引用
收藏
页码:1814 / 1821
页数:8
相关论文
共 31 条
  • [1] Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia
    Aricò, M
    Valsecchi, MG
    Camitta, B
    Schrappe, M
    Chessells, J
    Baruchel, A
    Gaynon, P
    Silverman, L
    Janka-Schaub, G
    Kamps, W
    Pui, CH
    Masera, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (14) : 998 - 1006
  • [2] Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study
    Balduzzi, A
    Valsecchi, MG
    Uderzo, C
    De Lorenzo, P
    Klingebiel, T
    Peters, C
    Stary, J
    Felice, MS
    Magyarosy, E
    Conter, V
    Reiter, A
    Messina, C
    Gadner, H
    Schroppe, M
    [J]. LANCET, 2005, 366 (9486) : 635 - 642
  • [3] Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study
    Eapen, Mary
    Rubinstein, Pablo
    Zhang, Mei-Jie
    Stevens, Cladd
    Kurtzberg, Joanne
    Scaradavou, Andromachi
    Loberiza, Fausto R.
    Champlin, Richard E.
    Klein, John P.
    Horowitz, Mary M.
    Wagner, John E.
    [J]. LANCET, 2007, 369 (9577) : 1947 - 1954
  • [4] Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
    Finke, Juergen
    Bethge, Wolfgang A.
    Schmoor, Claudia
    Ottinger, Hellmut D.
    Stelljes, Matthias
    Zander, Axel R.
    Volin, Liisa
    Ruutu, Tapani
    Heim, Dominik A.
    Schwerdtfeger, Rainer
    Kolbe, Karin
    Mayer, Jiri
    Maertens, Johan A.
    Linkesch, Werner
    Holler, Ernst
    Koza, Vladimir
    Bornhaeuser, Martin
    Einsele, Hermann
    Kolb, Hans-Jochem
    Bertz, Hartmut
    Egger, Matthias
    Grishina, Olga
    Socie, Gerard
    [J]. LANCET ONCOLOGY, 2009, 10 (09) : 855 - 864
  • [5] Indications and results of cord blood transplant in children with leukemia
    Gluckman, E.
    Rocha, V.
    [J]. BONE MARROW TRANSPLANTATION, 2008, 41 (Suppl 2) : S80 - S82
  • [6] Human leukocyte antigen matching in cord blood transplantation
    Gluckman, E
    Koegler, G
    Rocha, V
    [J]. SEMINARS IN HEMATOLOGY, 2005, 42 (02) : 85 - 90
  • [7] Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice
    Gluckman, E
    Rocha, V
    Arcese, W
    Michel, G
    Sanz, G
    Chan, KW
    Takahashi, TA
    Ortega, J
    Filipovich, A
    Locatelli, F
    Asano, S
    Fagioli, F
    Vowels, M
    Sirvent, A
    Laporte, JP
    Tiedemann, K
    Amadori, S
    Abecassis, M
    Bordigoni, P
    Diez, B
    Shaw, PJ
    Vora, A
    Caniglia, M
    Garnier, F
    Ionescu, I
    Garcia, J
    Koegler, G
    Rebulla, P
    Chevret, S
    [J]. EXPERIMENTAL HEMATOLOGY, 2004, 32 (04) : 397 - 407
  • [8] Cord blood transplantation for children with acute leukaemia: a Eurocord registry analysis
    Gluckman, E
    Rocha, V
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 2004, 33 (03) : 271 - 273
  • [9] CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS
    GLUCKSBERG, H
    STORB, R
    FEFER, A
    BUCKNER, CD
    NEIMAN, PE
    CLIFT, RA
    LERNER, KG
    THOMAS, ED
    [J]. TRANSPLANTATION, 1974, 18 (04) : 295 - 304
  • [10] Hough R, 2007, BONE MARROW TRANSPL, V39, pS3